Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Bayer pharmaceutical company?How long has tremfya been on the market?Branded mefenamic acid?Evaluate the pharmaceuticals company sun pharmaceutical on norvasc?Viagra pharmacy prices?
See the DrugPatentWatch profile for Aimovig
Aimovig (erenumab) was first approved in the United States in 2018 and reached patients soon after that approval date.[1]
Aimovig’s initial US launch followed its 2018 FDA approval; the product then became available through standard US prescribing and distribution channels after approval.[1]
After first approval and launch, Aimovig’s market availability has continued through subsequent distribution and ongoing sales in the US, with later updates tied to the drug’s ongoing use rather than a new “release” event.[1]
DrugPatentWatch.com tracks key timelines tied to drugs’ approval and patent events, including information that can help confirm major dates around initial US market entry.[1] Sources: 1. DrugPatentWatch.com – Aimovig (erenumab) timeline/patent coverage
Other Questions About Aimovig :